Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Sanabria Bohorquez

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|September 19, 2003
Quantification of human brain benzodiazepine receptors using [18F]fluoroethylflumazenil: a first report in volunteers and epileptic patientsPhilippe Levêque, Sandra Sanabria-Bohorquez, Anne Bol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 2, 2025
In Vivo Head-to-Head Comparison of [<sup>18</sup>F]GTP1 with [<sup>18</sup>F]MK-6240 and [<sup>18</sup>F]PI-2620 in Alzheimer DiseaseEmily Olafson, Matteo Tonietto, Gregory Klein, et al.
Nuclear Medicine Communications|September 5, 2008
Biodistribution and radiation dosimetry of [18F]F-PEB in nonhuman primatesMarie-José Bélanger, Stephen M Krause, Christine Ryan, et al.
Journal of Alzheimer'S Disease : JAD|January 13, 2025
Cross-sectional and prognostic associations of baseline [<sup>18</sup>F]GTP1 tau PET signal and white matter lesion volumes for cognitive and functional decline in prodromal-to-mild Alzheimer's diseaseNancy E Ruiz-Uribe, Paul Manser, Brandon Butcher, et al.
Alzheimer'S Research & Therapy|December 2, 2021
Baseline [<sup>18</sup>F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's diseaseEdmond Teng, Paul T Manser, Sandra Sanabria Bohorquez, et al.
Neurobiology of Aging|July 8, 2019
Cross-sectional associations between [<sup>18</sup>F]GTP1 tau PET and cognition in Alzheimer's diseaseEdmond Teng, Michael Ward, Paul T Manser, et al.
Journal of Nuclear Medicine Technology|October 13, 2019
Optimization of <sup>89</sup>Zr PET Imaging for Improved Multisite Quantification and Lesion Detection Using an Anthropomorphic PhantomPaul E Christian, Simon-Peter Williams, Lance Burrell, et al.
Investigational New Drugs|August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
JAMA Neurology|June 13, 2022
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical TrialEdmond Teng, Paul T Manser, Karen Pickthorn, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|July 10, 2023
CenTauR: Toward a universal scale and masks for standardizing tau imaging studiesVictor L Villemagne, Antoine Leuzy, Sandra Sanabria Bohorquez, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
European Journal of Nuclear Medicine and Molecular Imaging|September 19, 2003
Quantification of human brain benzodiazepine receptors using [18F]fluoroethylflumazenil: a first report in volunteers and epileptic patientsPhilippe Levêque, Sandra Sanabria-Bohorquez, Anne Bol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 2, 2025
In Vivo Head-to-Head Comparison of [<sup>18</sup>F]GTP1 with [<sup>18</sup>F]MK-6240 and [<sup>18</sup>F]PI-2620 in Alzheimer DiseaseEmily Olafson, Matteo Tonietto, Gregory Klein, et al.
Nuclear Medicine Communications|September 5, 2008
Biodistribution and radiation dosimetry of [18F]F-PEB in nonhuman primatesMarie-José Bélanger, Stephen M Krause, Christine Ryan, et al.
Journal of Alzheimer'S Disease : JAD|January 13, 2025
Cross-sectional and prognostic associations of baseline [<sup>18</sup>F]GTP1 tau PET signal and white matter lesion volumes for cognitive and functional decline in prodromal-to-mild Alzheimer's diseaseNancy E Ruiz-Uribe, Paul Manser, Brandon Butcher, et al.
Alzheimer'S Research & Therapy|December 2, 2021
Baseline [<sup>18</sup>F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's diseaseEdmond Teng, Paul T Manser, Sandra Sanabria Bohorquez, et al.
Neurobiology of Aging|July 8, 2019
Cross-sectional associations between [<sup>18</sup>F]GTP1 tau PET and cognition in Alzheimer's diseaseEdmond Teng, Michael Ward, Paul T Manser, et al.
Journal of Nuclear Medicine Technology|October 13, 2019
Optimization of <sup>89</sup>Zr PET Imaging for Improved Multisite Quantification and Lesion Detection Using an Anthropomorphic PhantomPaul E Christian, Simon-Peter Williams, Lance Burrell, et al.
Investigational New Drugs|August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
JAMA Neurology|June 13, 2022
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical TrialEdmond Teng, Paul T Manser, Karen Pickthorn, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|July 10, 2023
CenTauR: Toward a universal scale and masks for standardizing tau imaging studiesVictor L Villemagne, Antoine Leuzy, Sandra Sanabria Bohorquez, et al.
Pageof 2